Search

Your search keyword '"Borruel N"' showing total 145 results
Start Over Author "Borruel N"
145 results on '"Borruel N"'

1. P798 Study of the concordance between the enzymatic activity of Thiopurine S-methyltransferase and polymorphisms in the TPMT gene in patients with Inflammatory Bowel Disease

Author

Céspedes Martínez, E, primary, Robles-Alonso, V, additional, Castellote, L, additional, Bravo-Nieto, D, additional, Serra, X, additional, Herrera-De Guise, C, additional, Mayorga, L, additional, Pérez, Z, additional, Oller, E, additional, Garriga-Edo, S, additional, Casellas, F, additional, and Borruel, N, additional

Published
2024
Full Text
View/download PDF

3. P883 Impaired long-term quantitative cellular response to SARS-COV-2 vaccine in thiopurine-treated IBD patients

Author

Mayorga Ayala, L F, primary, Herrera-deGuise, C, additional, Esperalba, J, additional, Martinez-Gomez, X, additional, Céspedes Martinez, E, additional, Serra Ruiz, X, additional, Robles, V, additional, Lastiri, E, additional, Perez, Z, additional, Oller, E, additional, Fernandez-Naval, C, additional, Martinez-Gallo, M, additional, Casellas, F, additional, and Borruel, N, additional

Published
2024
Full Text
View/download PDF

10. P588 T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment

Author

Mayorga Ayala, L F, primary, Herrera-deGuise, C, additional, Esperalba, J, additional, Martinez-Gomez, X, additional, Céspedes Martinez, E, additional, Robles Alonso, V, additional, Jimenez, A, additional, Perez Martinez, Z, additional, Oller, E, additional, Ibarz, A, additional, Fernandez-Naval, C, additional, Martinez-Gallo, M, additional, Lopez Messeguer, M, additional, Casellas, F, additional, and Borruel, N, additional

Published
2022
Full Text
View/download PDF

16. Increased mucosal tumour necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. (Inflammatory Bowel Disease)

Author

Borruel, N., Carol, M., Casellas, F., Antolin, M., Lara, F. de, Espin, E, Naval, J., Guarner, F., and Malagelada, J.R.

Subjects
Inflammation -- Causes of -- Complications and side effects, Tumor necrosis factor -- Physiological aspects, Crohn's disease -- Complications and side effects, Health
Abstract

Background and aims: Tumour necrosis factor a (TNF-.α) plays a key role in the pathogenesis of intestinal inflammation in Crohn's disease. The effect of bacteria on TNF-α release by intestinal [...]

Published
2002

20. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes

Author

Nielsen, H.B., Almeida, M., Sierakowska Juncker, A., Rasmussen, S., Li, J., Sunagawa, S., Plichta, D.R., Gautier, L., Pedersen, A.G., Le Chatelier, E., Pelletier, E., Bonde, I., Nielsen, T., Manichanh, C., Arumugam, M., Batto, J.M., Quintanilha dos Santos, M.B., Blom, N., Borruel, N., Burgdorf, K.S., Boumezbeur, F., Casellas, F., Doré, J., Dworzynski, P., Guarner, F., Hansen, T., Hildebrand, F., Kaas, R.S., Kennedy, S., Kristiansen, K., Kultima, J.R., Leonard, P., Levenez, F., Lund, O., Moumen, B., Le Paslier, D., Pons, N., Pedersen, O., Prifti, E., Qin, J., Raes, J., Sørensen, S., Tap, J., Tims, S., Ussery, D.W., Yamada, T., Jamet, A., Mérieux, A., Cultrone, A., Torrejon, A., Quinquis, B., Brechot, C., Delorme, C., M'Rini, C., de Vos, W.M., Maguin, E., Varela, E., Guedon, E., Gwen, F., Haimet, F., Artiguenave, F., Vandemeulebrouck, G., Denariaz, G., Khaci, G., Blottière, H., Knol, J., Weissenbach, J., van Hylckama Vlieg, J.E., Torben, J., Parkhil, J., Turner, K., van de Guchte, M., Antolin, M., Rescigno, M., Kleerebezem, M., Derrien, M., Galleron, N., Sanchez, N., Grarup, N., Veiga, P., Oozeer, R., Dervyn, R., Layec, S., Bruls, T., Winogradski, Y., Zoetendal, E.G., Renault, D., Sicheritz-Ponten, Bork, P., Wang, J., Brunak, S., Ehrlich, S.D., Center for Biological Sequence Analysis, Technical University of Denmark [Lyngby] (DTU), Novo Nordisk Foundation Center for Biosustainability, MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Department of Computer Science [Baltimore], Johns Hopkins University (JHU), BGI Hong Kong Researche Institute, BGI Shenzhen, School of Bioscience and Biotechnology, Southern University of Science and Technology [Shenzhen] (SUSTech), European Molecular Biology Laboratory, US 1367 MetaGénoPolis, Institut National de la Recherche Agronomique (INRA)-Département Microbiologie et Chaîne Alimentaire (MICA), Institut National de la Recherche Agronomique (INRA)-MetaGénoPolis (MGP), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Université d'Évry-Val-d'Essonne (UEVE), Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR), Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Digestive System Research Unit, Vall d'Hebron University Hospital [Barcelona], Faculty of Health Sciences, University of Southern Denmark (SDU), Department of Structural Biology, Flanders Institute for Biotechnology, Department of Bioscience Engineering, Vrije Universiteit [Brussels] (VUB), 8National Food Institute - Division for Epidemiology and Microbial Genomics, Department of Biology [Copenhagen], Faculty of Science [Copenhagen], Hagedorn Research Institute, Faculty of Health, Aarhus University [Aarhus], BGI Hong Kong research Institute, Rega Institute - Department of Microbiology and Immunology, Université Catholique de Louvain (UCL), VIB Center for the Biology of Disease, Section of Microbiology [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Faculty of Science [Copenhagen], Laboratory of Microbiology, Wageningen University and Research Centre [Wageningen] (WUR), Department of Biological Information, Tokyo Institute of Technology [Tokyo] (TITECH), Max-Delbrück Center for Molecular Medicine, Princess Al Jawhara Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, Centre for Host-Microbiome Interactions, Dental Institute Central Office, Guy’s Hospital, King‘s College London, Département Microbiologie et Chaîne Alimentaire (MICA), Institut National de la Recherche Agronomique (INRA), European Community's Seventh Framework Programme [FP7-HEALTH-F4-2007-201052, FP7-HEALTH-2010-261376], OpenGPU FUI collaborative research projects, DGCIS, Instituto de Salud Carlos III (Spain), Ministere de la Recherche et de l'Education Nationale (France), [ANR-11-DPBS-0001], Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Beijing Genomics Institute [Shenzhen] (BGI), Southern University of Science and Technology (SUSTech), MetaGenoPolis, Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Vrije Universiteit Brussel (VUB), Université Catholique de Louvain = Catholic University of Louvain (UCL), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Faculty of Science [Copenhagen], Wageningen University and Research [Wageningen] (WUR), Max Delbrück Center for Molecular Medicine [Berlin] (MDC), Helmholtz-Gemeinschaft = Helmholtz Association, European Project: 201052,EC:FP7:HEALTH,FP7-HEALTH-2007-A,METAHIT(2008), Department of Systems Biology, Center for Biological Sequence Analysis, Ctr Biol Sequence Anal, National University of Singapore (NUS), European Molecular Biology Laboratory [Heidelberg] (EMBL), Department of Mathematics and Computer Science [Odense] (IMADA), Génomique métabolique (UMR 8030), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Vall d’Hebron Research Institute (VHIR), Faculty of Health and Medical Sciences, The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen = Københavns Universitet (KU), INRA US1367 MetaGenoPolis, European Molecular Biology Laboratory [Grenoble] (EMBL), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Center for Biological Sequence Analysis [Lyngby], Chinese Academy of Agricultural Mechanization Sciences (CCCME), 1Génétique Microbienne, INRA, Domaine de Vilvert, 78352 Jouy en Josas Cedex, and Department of Bio-engineering Sciences

Subjects
Cellular immunity, polypeptide, [SDV]Life Sciences [q-bio], SHORT READ ALIGNMENT SEQUENCES SYSTEMS ALGORITHMS MICROBIOTA PROTEIN LIFE SETS TREE TOOL, complex metagenomic sample, Applied Microbiology and Biotechnology, Genome, Microbiologie, Databases, Genetic, genetic element, Cluster Analysis, sets, short read alignment, ComputingMilieux_MISCELLANEOUS, Genetics, 0303 health sciences, tool, metagenomic, tree, Lactococcus lactis, IL-12, Molecular Medicine, Biotechnology, life, Microbial Genomes, antigen specific immune response, Biomedical Engineering, Bioengineering, Computational biology, [SDV.BID]Life Sciences [q-bio]/Biodiversity, cellular immunity, Biology, algorithms, Microbiology, 03 medical and health sciences, Genetic variation, microbiota, Microbiome, Gene, genome, 030304 developmental biology, adjuvant activity, VLAG, 030306 microbiology, Metagenomics, WIAS, Microbial genetics, sequences, systems, protein
Abstract

Most current approaches for analyzing metagenomic data rely on comparisons to reference genomes, but the microbial diversity of many environments extends far beyond what is covered by reference databases. De novo segregation of complex metagenomic data into specific biological entities, such as particular bacterial strains or viruses, remains a largely unsolved problem. Here we present a method, based on binning co-abundant genes across a series of metagenomic samples, that enables comprehensive discovery of new microbial organisms, viruses and co-inherited genetic entities and aids assembly of microbial genomes without the need for reference sequences. We demonstrate the method on data from 396 human gut microbiome samples and identify 7,381 co-abundance gene groups (CAGs), including 741 metagenomic species (MGS). We use these to assemble 238 high-quality microbial genomes and identify affiliations between MGS and hundreds of viruses or genetic entities. Our method provides the means for comprehensive profiling of the diversity within complex metagenomic samples.

Published
2014

25. Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation

Author

Universitat Rovira i Virgili, Serena C., Keiran N., Madeira A., Maymó-Masip E., Ejarque M., Terrón-Puig M., Espin E., Martí M., Borruel N., Guarner F., Menacho M., Zorzano A., Millan M., Fernández-Veledo S., Vendrell J., Universitat Rovira i Virgili, and Serena C., Keiran N., Madeira A., Maymó-Masip E., Ejarque M., Terrón-Puig M., Espin E., Martí M., Borruel N., Guarner F., Menacho M., Zorzano A., Millan M., Fernández-Veledo S., Vendrell J.

Abstract

Crohn's disease (CD) is characterized by the expansion of mesenteric fat, also known as "creeping fat." We explored the plasticity and immune properties of adipose-derived stem cells (ASCs) in the context of CD as potential key players in the development of creeping fat. Mesenteric CD-derived ASCs presented a more proliferative, inflammatory, invasive, and phagocytic phenotype than equivalent cells from healthy donors, irrespective of the clinical stage. Remarkably, ASCs from the subcutaneous depot of patients with CD also showed an activated immune response that was associated with a reduction in their immunosuppressive properties. The invasive phenotype of mesenteric CD ASCs was governed by an inflammasome-mediated inflammatory state since blocking inflammasome signaling, mainly the secretion of interleukin-1?, reversed this characteristic. Thus, CD alters the biological functions of ASCs as adipocyte precursors, but also their immune properties. Selection of ASCs with the best immunomodulatory properties is advocated for the success of cell-based therapies.Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Published
2017

26. Enterotypes of the human gut microbiome

Author

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dorxe9 J, MetaHIT Consortium, Antolxedn M, Artiguenave F, Blottiere HM, Almeida M, Brechot, Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dorxe9 J, MetaHIT Consortium, Antolxedn M, Artiguenave F, Blottiere HM, Almeida M, and Brechot

Published
2011

27. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease

Author

Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, and Borruel N

Subjects
digestive system diseases
Abstract

Inflammatory bowel disease (IBD) is a debilitating immune disorder that impairs function and health-related quality of life (HRQOL). A goal of IBD treatment is mucosal healing, but it is not known whether it achieves normalization of the patients' perception of health. This can be assessed by using a cut-off scoring threshold of the Inflammatory Bowel Disease Questonnaire-36 (IBDQ-36).

Published
2012

28. Enterotypes of the human gut microbiome

Author

Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, Takuji, Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., Batto, J. M., Bertalan, M., Borruel, N., Casellas, F., Fernandez, L., Gautier, L., Hansen, T., Hattori, M., Hayashi, T., Kleerebezem, M., Kurokawa, K., Leclerc, M., Levenez, F., Manichanh, C., Nielsen, H. B., Nielsen, T., Pons, N., Poulain, J., Qin, J., Sicheritz-Ponten, T., Tims, S., Torrents, D., Ugarte, E., Zoetendal, E. G., Wang, J., Guarner, F., Pedersen, O., de Vos, W. M., Brunak, S., Dor�, J., Antol匤, M., Artiguenave, F., Blottiere, H. M., Almeida, M., Brechot, C., Cara, C., Chervaux, C., Cultrone, A., Delorme, C., Denariaz, G., Dervyn, R., Foerstner, K. U., Friss, C., van de Guchte, M., Guedon, E., Haimet, F., Huber, W., van Hylckama-Vlieg, J., Jamet, A., Juste, C., Kaci, G., Knol, J., Lakhdari, O., Layec, S., Le Roux, K., Maguin, E., M駻ieux, A., Melo Minardi, R., M'rini, C., Muller, J., Oozeer, R., Parkhill, J., Renault, P., Rescigno, M., Sanchez, N., Sunagawa, S., Torrejon, A., Turner, K., Vandemeulebrouck, G., Varela, E., Winogradsky, Y., Zeller, G., Weissenbach, J., Ehrlich, S. D., Bork, P., Consortium, MetaHIT, Microbiota Interaction with Human and Animal (MIHA), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech-Institut National de la Recherche Agronomique (INRA)-AgroParisTech, AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), European Molecular Biology Laboratory [Heidelberg] (EMBL), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Center for Biological Sequence Analysis [Lyngby], Technical University of Denmark [Lyngby] (DTU), Digestive System Research Unit, Vall d'Hebron University Hospital [Barcelona], Barcelona Supercomputing Center - Centro Nacional de Supercomputacion (BSC - CNS), Centre Interlangues - Texte, Image, Langage (TIL), Université de Bourgogne (UB), Hagedorn Research Institute, Faculty of Health Sciences, University of Southern Denmark (SDU), NIZO [Ede, Netherlands], Institut National de la Recherche Agronomique (INRA), Génomique métabolique (UMR 8030), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Beijing Genomics Institute [Shenzhen] (BGI), Laboratory of Microbiology, Wageningen University and Research [Wageningen] (WUR), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Lundbeck Foundation Centre for Applied Medical Genomics in Personalized Disease Prediction, Prevention and Care (LuCAMP), Novo Nordisk Foundation, International Science and Technology Cooperation Project in China [0806], Agence Nationale de la Recherche (ANR), Institute for the encouragement of Scientific Research and Innovation of Brussels (ISRIB), Fund for Scientific Research Flanders (FWO), European Project: 201052,EC:FP7:HEALTH,FP7-HEALTH-2007-A,METAHIT(2008), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, NIZO FOOD RESEARCH (NIZO), Nizo food research, Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Université d'Évry-Val-d'Essonne (UEVE), Wageningen University and Research Centre [Wageningen] (WUR), Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, intestinal microbiota, catalog, obesity, [SDV]Life Sciences [q-bio], pathways, Biodiversity, Biology, Microbiology, Article, diversity, 03 medical and health sciences, Feces, Human gut, mucin, Phylogenetics, Microbiologie, Humans, bacterial, Microbiome, genes, Phylogeny, 030304 developmental biology, VLAG, 2. Zero hunger, 0303 health sciences, metagenomics, Multidisciplinary, Bacteria, colon, 030306 microbiology, Host (biology), Ecology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Bacterial Typing Techniques, Europe, Intestines, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Evolutionary biology, Metagenomics, Metagenome, Enterotype, Biological Markers, Female, Biomarkers, Human Microbiome Project
Abstract

International audience; Our knowledge of species and functional composition of the human gut microbiome is rapidly increasing, but it is still based on very few cohorts and little is known about variation across the world. By combining 22 newly sequenced faecal metagenomes of individuals from four countries with previously published data sets, here we identify three robust clusters (referred to as enterotypes hereafter) that are not nation or continent specific. We also confirmed the enterotypes in two published, larger cohorts, indicating that intestinal microbiota variation is generally stratified, not continuous. This indicates further the existence of a limited number of well-balanced host-microbial symbiotic states that might respond differently to diet and drug intake. The enterotypes are mostly driven by species composition, but abundant molecular functions are not necessarily provided by abundant species, highlighting the importance of a functional analysis to understand microbial communities. Although individual host properties such as body mass index, age, or gender cannot explain the observed enterotypes, data-driven marker genes or functional modules can be identified for each of these host properties. For example, twelve genes significantly correlate with age and three functional modules with the body mass index, hinting at a diagnostic potential of microbial markers.

Published
2011

29. The opinion of patients with inflammatory bowel disease on healthcare received

Author

Casellas, F., Fontanet, G., Borruel, N., and Malagelada, J. R.

Subjects
Information resources, Crohn's disease, Ulcerative colitis, Enfermedad inflamatoria intestinal, Colitis ulcerosa, Health care, Atención sanitaria, Enfermedad de Crohn, Inflammatory bowel disease, Recursos sanitarios
Abstract

Backgrounds and aim: an item to consider in analyzing a healthcare model for a population group suffering from chronic disease is necessary health-care resources, their use, and their rating by endusers. Regarding inflammatory bowel disease (IBD), healthcare resources used by patients are numerous and varied, and yet they have been never assessed. Design: an anonymous self-rated questionnaire has been developed with 24 basic questions on overall disease, who is monitoring the patient, how are visits scheduled, need for urgent care, patient view on how control may be improved, etc. This questionnaire was sent to 393 patients who were asked to fill it out and then return it by mail. Results: two hundred and thirty-seven patients returned a filled-out questionnaire. Most patients were followed up in a hospital, and only 8.8% were being monitored by a general practitioner or area specialist. Ninety-two percent of patients reported visits were routinely scheduled irrespective of clinical status, and 79.6% of patients reported having occasionally presented to an emergency department, because of not knowing what to do or due to having no other resources available in 25.2% of times. This entails that 38% of visits to an emergency unit may be prevented with a better understanding of disease or by means of a phone call. Thirty percent of patients reported that current healthcare is inadequate in terms of contents, form, or waiting time. In all, 97.8% of patients feel that information and knowledge on their disease would help in its control, and 69.6% consider that adequate information would allow them to initiate a proper treatment before visiting their doctor. Family care is another poorly lookedafter aspect that 74.6% of subjects believe would be of help in controlling their disease. Conclusions: overall, the opinion of patients with IBD on healthcare received is good; however, a number of deficiencies were detected, as is the case with insufficient information, care of family members, and healthcare resources accessibility/agility. Fundamento: un elemento a tener en cuenta al analizar un modelo de atención sanitaria dirigido a un grupo de población afecta de una enfermedad crónica es el de los recursos sanitarios necesarios, su utilización y la valoración que tienen los usuarios de ellos. En la enfermedad inflamatoria intestinal (EII) los recursos sanitarios utilizados por los enfermos son numerosos y variados, pero no han sido evaluados. Diseño: se ha realizado una encuesta autorrellenable anónima de 24 preguntas básicas a cerca de datos generales de la enfermedad, quién les controla, cómo se programan las visitas, necesidad de atención urgente, cómo creen que se puede mejorar su control, etc. La encuesta se remitió al domicilio de 393 pacientes para su contestación y se les pidió que la devolvieran por correo. Resultados: doscientos treinta y siete pacientes devolvieron la encuesta cumplimentada. La mayoría de los pacientes eran controlados en un hospital, y sólo el 8,8% lo eran por el médico de cabecera o especialista de zona. El 92% de pacientes refieren que las visitas se programan de forma rutinaria, independientemente del estado clínico. El 79,6% de pacientes refiere haber acudido alguna vez a urgencias, siendo el motivo en el 25,2% de las ocasiones no saber qué hacer o no tener otro recurso disponible. Ello explica que el 38% de visitas al servicio de urgencias se podrían haber evitado con un mejor conocimiento de la enfermedad o una consulta telefónica. El 30% de pacientes refiere que la actual atención sanitaria es inadecuada, ya sea por su contenido, la forma o el tiempo de espera. El 97,8% de pacientes cree que la información y conocimiento de la enfermedad ayudarían a su control, de forma que el 69,6% considera que con la información adecuada podrían iniciar el tratamiento ya antes de la visita médica. Otro aspecto poco atendido, y que el 74,6% de pacientes opina que ayudaría al control de la enfermedad, es la atención a su entorno familiar. Conclusiones: la opinión general de los pacientes con EII sobre la atención sanitaria recibida es, en general buena, sin embargo se detectan carencias como la información insuficiente, el cuidado al entorno familiar y la accesibilidad-agilidad de los recursos sanitarios.

Published
2004

47. The Impact of Delaying Gastric Emptying by Either Meal Substrate or Drug on the [13C]-Urea Breath Test.

Author

Casellas, F., Lopez, J., Borruel, N., Saperas, E., Vergara, M., De Torres, I., Armengol, J. R., and Malagelada, J.-R.

Subjects
HELICOBACTER pylori infections, BREATH tests, UREA, HELICOBACTER pylori, DOPA
Abstract

Objective: Optimal [13C]-urea breath test (UBT) conditions for diagnosis of Helicobacter pylori infection are still being fine-tuned. In the present study we investigated the impact of delaying gastric emptying by different meal substrates or L-DOPA, a drug known to induce gastric stasis, on the performance of the [13C]-UBT. Methods: A total of 115 patients participated in the study. On two consecutive days, participants ingested [13C]-urea (100 mg) 10 min after either 270 ml of a mixed formula meal (1 Kcal/ml) or an equivalent amount of tap water. In 11 participants two additional tests were performed with or without oral 500 mg L-DOPA given 30 min before [13C]-urea load. The 13C/12C ratio in a basal breath sample was compared with ratios in samples collected 30 and 60 min after [13C]-urea. Histological assessment of H. pylori presence in antral biopsy served as reference standard. Results: Formula UBT showed excellent specificity (100% at 30 and 60 min) and good sensitivity (97% at both time intervals), whereas water UBT had the same specificity but slightly lower sensitivity (94% at 30 min and 73% at 60 min). In formula UBT, 13C/12C ratios were higher at 60 min than at 30 min (21.7 ± 2 vs 17.7 ± 1.8‰ respectively.; p < 0.01, whereas in water UBT 13C/12C ratios were higher at 30 min than at 60 min (13.9 ± 1.5 vs 8.4 ± 0.09‰ respectively, p < 0.01). Pretreatment with L-DOPA did not modify either the sensitivity or the specificity of the UBT. Conclusions: The performance of the [13C]-urea with a formula meal may not be improved by pharmacologically delaying gastric emptying. A short, water-based test may be a sensible approach to worldwide standardization of the [13C]-UBT for H. pylori infection. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

48. Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis

Author

Casellas, F., Antoli@?n, M., Varela, E., Garci@?a-lafuente, A., Guarner, F., Borruel, N., Armengol Miro, J.R., and Malagelada, J.R.

Abstract

Background & Aims: Several indices evaluate disease activity in ulcerative colitis, but most have drawbacks to their application (invasiveness, complexity, or lack of specificity), and discrepancies between them are frequent. Assuming that desquamation of epithelial and inflammatory cells increases in damaged colonic mucosa, we hypothesized that fecal excretion of human DNA is an index of mucosal inflammation and damage. The aim of our study was to determine whether excretion of human DNA is useful in the evaluation of disease activity in ulcerative colitis. Methods: Thirty-one controls and 36 ulcerative colitis patients were included. Ulcerative colitis patients and controls underwent colonoscopic examination after preparation by gut lavage with polyethylene-glycol electrolyte solution. In patients, disease activity was established using the clinical index of Rachmilewitz and an endoscopic score. Feces and gut lavage fluid were obtained and DNA levels were measured by quantitative polymerase chain reaction of the human @b-globin gene. Results: Fecal DNA excretion correlated with the clinical index (r = 0.59, P < 0.05) and the endoscopic score (r = 0.76, P < 0.01). Gut lavage fluid DNA levels also correlated with clinical and endoscopic activity scores (r = 0.41 and 0.51, respectively, P < 0.05). Fecal DNA excretion was significantly higher in patients with endoscopically or clinically active disease than in controls or patients in remission. Fecal DNA excretion discriminates between endoscopically active disease and remission (sensitivity 0.67, specificity 1.00, P < 0.01). Conclusions: Excretion of human DNA in feces, as an expression of cellular desquamation, is a novel noninvasive technique to objectively assess disease activity in ulcerative colitis.

Published
2004
Full Text
View/download PDF

50. Intercontinental Gut Microbiome Variances in IBD

Author

Luis Mayorga, Gerard Serrano-Gómez, Zixuan Xie, Natalia Borruel, Chaysavanh Manichanh, Institut Català de la Salut, [Mayorga L] Laboratori de Microbiota, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Serrano-Gómez G] Laboratori de Microbiota, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Xie Z, Manichanh C] Laboratori de Microbiota, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Borruel N] Laboratori de Microbiota, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat d’Atenció Crohn-Colitis, Servei d’Aparell Digestiu, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
fenómenos microbiológicos::microbiota::microbiota intestinal [FENÓMENOS Y PROCESOS], IBD, Otros calificadores::/diagnóstico [Otros calificadores], Biological Factors::Biomarkers [CHEMICALS AND DRUGS], factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS], Catalysis, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES], Inorganic Chemistry, microbiome, geography, Feces, Crohn Disease, Other subheadings::/diagnosis [Other subheadings], Humans, Intestins - Microbiologia, Physical and Theoretical Chemistry, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES], Molecular Biology, Spectroscopy, Microbiological Phenomena::Microbiota::Gastrointestinal Microbiome [PHENOMENA AND PROCESSES], Geography, Organic Chemistry, General Medicine, Inflammatory Bowel Diseases, Computer Science Applications, Gastrointestinal Microbiome, Intestins - Inflamació - Diagnòstic, Marcadors bioquímics, Colitis, Ulcerative, Microbiome, Biomarkers
Abstract

Geography; Microbiome Geografía; Microbioma Geografia; Microbioma The development of biomarkers for inflammatory bowel disease (IBD) diagnosis would be relevant in a generalized context. However, intercontinental investigation on these microbial biomarkers remains scarce. We examined taxonomic microbiome variations in IBD using published DNA shotgun metagenomic data. For this purpose, we used sequenced data from our previous Spanish Crohn’s disease (CD) and ulcerative colitis (UC) cohort, downloaded sequence data from a Chinese CD cohort, and downloaded taxonomic and functional profiling tables from a USA CD and UC cohort. At the global level, geographical location and disease phenotype were the main explanatory covariates of microbiome variations. In healthy controls (HC) and UC, geography turned out to be the most important factor, while disease intestinal location was the most important one in CD. Disease severity correlated with lower alpha-diversity in UC but not in CD. Across geography, alpha-diversity was significantly different independently of health status, except for CD. Despite recruitment from different countries and with different disease severity scores, CD patients may harbor a very similar microbial taxonomic profile. Our study pointed out that geographic location, disease activity status, and other environmental factors are important contributing factors in microbiota changes in IBD. We therefore strongly recommend taking these factors into consideration for future IBD studies to obtain globally valid and reproducible biomarkers. Z.X. received a fellowship from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Action, Innovative Training Network: FunHoMic; grant number 812969. Chaysavanh Manichanh received grants from the Instituto de Salud Carlos III/FEDER (PI17/00614; PI20/00130).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results